More from Investing
Charts of the Boston-based biotech to do not provide a compelling case to buy the stock.
Alico Inc.'s largest shareholder is distributing its shares to its members, which could lead to a supply glut that depresses the stock and makes it a value buy.
Forward earnings estimates for the S&P 500 continue to fade.
Shares of Replimune Group and Eyenovia have swung up and down in 2019 but should be on the rise next year.